ALK and lung adenocarcinoma: Besides, ALK fusions were firstly identified in 2007 and occurred in approximately 3–7% of all lung adenocarcinoma patients, and the most common form was echinoderm microtubule-associated protein-like 4/anaplastic lymphoma kinase (EML4-ALK) [15].